<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Microarray-based studies of skeletal muscle from patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and high-risk individuals have demonstrated that <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and reduced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> biogenesis co-exist early in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> independently of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is unknown whether reduced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> biogenesis or other transcriptional alterations co-exist with impaired insulin responsiveness in primary human muscle cells from patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using cDNA microarray technology and global pathway analysis with the Gene Map Annotator and Pathway Profiler (GenMapp 2.1) and Gene Set Enrichment Analysis (GSEA 2.0.1), we examined transcript levels in myotubes established from <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and matched <z:mp ids='MP_0001261'>obese</z:mp> healthy participants, who had been extensively metabolically characterised both in vivo and in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>We have previously reported reduced basal <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation and impaired insulin-stimulated <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthesis and <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation in these diabetic myotubes </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: No single gene was differently expressed after correction for multiple testing, and no biological pathway was differently expressed using either method of global pathway analysis </plain></SENT>
<SENT sid="5" pm="."><plain>In particular, we found no evidence for differential expression of genes involved in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> oxidative metabolism </plain></SENT>
<SENT sid="6" pm="."><plain>Consistently, there was no difference in <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of genes known to mediate the transcriptional control of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> biogenesis (PPARGC1A and NRF1) or in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> mass between diabetic and control myotubes </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: These results support the hypothesis that impaired <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> biogenesis is not a primary defect in the sequence of events leading to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>